STOCK TITAN

[Form 4] Becton, Dickinson and Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Michael Feld, EVP & President, Life Sciences at Becton, Dickinson and Company (BDX), reported a non-derivative disposition of 773 shares of BDX common stock on 08/20/2025. The filing uses transaction code F, and the explanatory note states these shares were withheld to satisfy tax withholding upon vesting of previously granted restricted stock units, so the reported price is shown as $0. After the withholding, Mr. Feld beneficially owned 8,417 shares directly. The Form 4 was signed by Donna Kalazdy by power of attorney on 08/22/2025.

Michael Feld, EVP e Presidente, Life Sciences di Becton, Dickinson and Company (BDX), ha riportato una cessione non derivativa di 773 azioni ordinarie BDX in data 20/08/2025. La segnalazione utilizza il codice transazione F e la nota esplicativa specifica che le azioni sono state trattenute per soddisfare le imposte alla scadenza di restricted stock units precedentemente concesse, pertanto il prezzo indicato è $0. Dopo la ritenuta, il Sig. Feld possedeva direttamente beneficiamente 8.417 azioni. Il Modulo 4 è stato firmato da Donna Kalazdy per procura in data 22/08/2025.

Michael Feld, EVP y Presidente de Life Sciences en Becton, Dickinson and Company (BDX), informó una disposición no derivativa de 773 acciones ordinarias de BDX el 20/08/2025. La presentación utiliza el código de transacción F y la nota explicativa indica que dichas acciones fueron retenidas para cubrir las retenciones fiscales al consolidarse unidades restringidas de acciones previamente otorgadas, por lo que el precio informado aparece como $0. Tras la retención, el Sr. Feld poseía beneficiariamente 8.417 acciones en propiedad directa. El Formulario 4 fue firmado por Donna Kalazdy por poder el 22/08/2025.

Michael Feld, Becton, Dickinson and Company(BDX)에서 Life Sciences 담당 EVP 겸 사장, 은 2025-08-20에 BDX 보통주 773주의 비파생 처분을 보고했습니다. 신고서에는 거래 코드 F가 사용되었고 설명란에는 이 주식들이 기존에 부여된 제한주(RSU)의 확정 시 세금 원천징수를 충족하기 위해 원천징수되었다고 기재되어 있어 보고된 가격은 $0로 표시됩니다. 원천징수 후 Feld 씨는 직접적으로 8,417주를 실소유하고 있었습니다. Form 4는 2025-08-22에 Donna Kalazdy가 위임장으로 서명했습니다.

Michael Feld, EVP et Président, Life Sciences chez Becton, Dickinson and Company (BDX), a déclaré une cession non dérivative de 773 actions ordinaires BDX le 20/08/2025. Le dépôt utilise le code de transaction F et la note explicative précise que ces actions ont été retenues pour couvrir les impôts dus lors de la levée d'unités d'actions restreintes précédemment attribuées, d'où le prix déclaré de 0 $. Après cette retenue, M. Feld détenait bénéficiairement 8 417 actions en propriété directe. Le formulaire 4 a été signé par Donna Kalazdy par procuration le 22/08/2025.

Michael Feld, EVP und President, Life Sciences bei Becton, Dickinson and Company (BDX), meldete am 20.08.2025 eine nicht-derivative Veräußerung von 773 Aktien der BDX-Stammaktien. Die Meldung verwendet den Transaktionscode F und der erläuternde Hinweis besagt, dass diese Aktien zur Begleichung der Steuerabzüge beim Vesting zuvor gewährter Restricted Stock Units einbehalten wurden, weshalb der gemeldete Preis mit $0 angegeben ist. Nach dem Einbehalt hielt Herr Feld direkt wirtschaftlich 8.417 Aktien. Das Formular 4 wurde am 22.08.2025 von Donna Kalazdy per Vollmacht unterschrieben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Insider withheld 773 shares for taxes after RSU vesting; small, routine change in holdings.

This Form 4 documents a tax-withholding disposition tied to vesting of previously reported restricted stock units, not an open-market sale or new compensation grant. The reduction of 773 shares to a post-transaction balance of 8,417 shares represents a routine settlement activity that does not change the executive's economic exposure meaningfully. There are no cash proceeds reported and no derivative activity disclosed.

TL;DR Filing reflects standard compliance with Section 16 reporting for RSU tax withholding.

The disclosure is consistent with standard equity compensation practices and shows timely reporting with a power-of-attorney signature. Because the transaction was a withholding for tax obligations, it does not indicate discretionary insider selling or a change in governance. No material governance or control implications are evident from the information provided.

Michael Feld, EVP e Presidente, Life Sciences di Becton, Dickinson and Company (BDX), ha riportato una cessione non derivativa di 773 azioni ordinarie BDX in data 20/08/2025. La segnalazione utilizza il codice transazione F e la nota esplicativa specifica che le azioni sono state trattenute per soddisfare le imposte alla scadenza di restricted stock units precedentemente concesse, pertanto il prezzo indicato è $0. Dopo la ritenuta, il Sig. Feld possedeva direttamente beneficiamente 8.417 azioni. Il Modulo 4 è stato firmato da Donna Kalazdy per procura in data 22/08/2025.

Michael Feld, EVP y Presidente de Life Sciences en Becton, Dickinson and Company (BDX), informó una disposición no derivativa de 773 acciones ordinarias de BDX el 20/08/2025. La presentación utiliza el código de transacción F y la nota explicativa indica que dichas acciones fueron retenidas para cubrir las retenciones fiscales al consolidarse unidades restringidas de acciones previamente otorgadas, por lo que el precio informado aparece como $0. Tras la retención, el Sr. Feld poseía beneficiariamente 8.417 acciones en propiedad directa. El Formulario 4 fue firmado por Donna Kalazdy por poder el 22/08/2025.

Michael Feld, Becton, Dickinson and Company(BDX)에서 Life Sciences 담당 EVP 겸 사장, 은 2025-08-20에 BDX 보통주 773주의 비파생 처분을 보고했습니다. 신고서에는 거래 코드 F가 사용되었고 설명란에는 이 주식들이 기존에 부여된 제한주(RSU)의 확정 시 세금 원천징수를 충족하기 위해 원천징수되었다고 기재되어 있어 보고된 가격은 $0로 표시됩니다. 원천징수 후 Feld 씨는 직접적으로 8,417주를 실소유하고 있었습니다. Form 4는 2025-08-22에 Donna Kalazdy가 위임장으로 서명했습니다.

Michael Feld, EVP et Président, Life Sciences chez Becton, Dickinson and Company (BDX), a déclaré une cession non dérivative de 773 actions ordinaires BDX le 20/08/2025. Le dépôt utilise le code de transaction F et la note explicative précise que ces actions ont été retenues pour couvrir les impôts dus lors de la levée d'unités d'actions restreintes précédemment attribuées, d'où le prix déclaré de 0 $. Après cette retenue, M. Feld détenait bénéficiairement 8 417 actions en propriété directe. Le formulaire 4 a été signé par Donna Kalazdy par procuration le 22/08/2025.

Michael Feld, EVP und President, Life Sciences bei Becton, Dickinson and Company (BDX), meldete am 20.08.2025 eine nicht-derivative Veräußerung von 773 Aktien der BDX-Stammaktien. Die Meldung verwendet den Transaktionscode F und der erläuternde Hinweis besagt, dass diese Aktien zur Begleichung der Steuerabzüge beim Vesting zuvor gewährter Restricted Stock Units einbehalten wurden, weshalb der gemeldete Preis mit $0 angegeben ist. Nach dem Einbehalt hielt Herr Feld direkt wirtschaftlich 8.417 Aktien. Das Formular 4 wurde am 22.08.2025 von Donna Kalazdy per Vollmacht unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feld Michael

(Last) (First) (Middle)
C/O BECTON, DICKINSON AND COMPANY
1 BECTON DRIVE

(Street)
FRANKLIN LAKES NJ 07417

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & President, Life Sciences
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/20/2025 F 773(1) D $0 8,417 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld for payment of withholding taxes in connection with vesting of previously reported restricted stock unit awards.
Remarks:
Donna Kalazdy, by power of attorney from Michael Feld 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael Feld report on the Form 4 for BDX?

The Form 4 reports a disposition of 773 shares on 08/20/2025 related to tax withholding for vested restricted stock units.

What does transaction code F mean on this Form 4?

Transaction code F indicates shares were withheld to satisfy tax withholding obligations in connection with vesting of equity awards.

How many BDX shares does Michael Feld own after the transaction?

Following the withholding, Mr. Feld beneficially owned 8,417 shares of BDX common stock.

Was any cash consideration reported from the transaction?

No cash proceeds were reported; the price is shown as $0, reflecting that shares were withheld to cover taxes rather than sold for cash.

Who signed the Form 4 and when?

The Form 4 was signed by Donna Kalazdy by power of attorney for Michael Feld on 08/22/2025.
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Latest News

BDX Latest SEC Filings

BDX Stock Data

57.10B
284.96M
0.57%
92.41%
1.91%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES